Recent studies have shown that most newly diagnosed epileptic patients can be satisfactorily treated with a single antiepileptic drug. We therefore undertook a prospective randomised pragmatic trial of the comparative efficacy and toxicity of four major antiepileptic drugs, utilised as monotherapy in newly diagnosed epileptic patients.
Abstract
Recent studies have shown that most newly diagnosed epileptic patients can be satisfactorily treated with a single antiepileptic drug. We therefore undertook a prospective randomised pragmatic trial of the comparative efficacy and toxicity of four major antiepileptic drugs, utilised as monotherapy in newly diagnosed epileptic patients.
Between 1981 and 1987 243 adult patients aged 16 years or over, newly referred to two district general hospitals with a minimum of two previously untreated tonic-clonic or partial with or without secondary generalised seizures were randomly allocated to treatment with phenobarbitone, phenytoin, carbamazepine, or sodium valproate. The protocol was designed to conform with standard clinical practice. Efficacy was assessed by time to first seizure after the start of treatment and time to enter one year remtission. The overall outcome with all of the four drugs was good with 27% remaining seizure free and 75% entering one year of remission by three years of follow up. No significant differences between the four drugs were found for either measure of efficacy at one, two, or three years of follow up. The overall incidence of-unacceptable side effects, necessitating withdrawal of the randomised drug, was 10%. For the individual drugs phenobarbitone (22%) was more likely to be withdrawn than phenytoin (3%), carbamazepine (11%), and sodium valproate (5%). In patients with newly diagnosed tonic-clonic or partial with or without secondary generalised seizures, the choice of drug will be more influenced by considerations of toxicity and costs. (7 Neurol Neurosurg Psychiatry 1995;58:44-50) Keywords: antiepileptic drugs; epilepsy; monotherapy trial Throughout most of this century there has been a widespread tendency to treat epileptic patients with polytherapy. After the advent of monitoring of antiepileptic drugs in blood, our own and other studies in the 1970s showed that there was much unnecessary polytherapyl and that the potential for single drug treatment was much greater than was appreciated, especially in newly diagnosed patients, in whom it was associated with excellent long term prognosis.2-5 By the end of that decade it became clear that it was necessary to undertake studies of the comparative efficacy and toxicity of all the major antiepileptic drugs in newly diagnosed patients. At the time we began our study in 1981 there was no information available on the comparative efficacy of any of the major antiepileptic drugs utilised as monotherapy in newly diagnosed epileptic patients and very little information on their comparative efficacy as add on treatment in chronic epileptic patients.6 Since then there have been reports of randomised monotherapy trials in newly diagnosed patients involving the comparison of two,7-9 three,'0 and four" drugs.
We present here the results of a long term open, randomised, pragmatic study of the comparative efficacy and toxicity of four widely used antiepileptic drugs (phenobarbitone, phenytoin, carbamazepine, and sodium valproate) in previously untreated, newly diagnosed, adult epileptic patients. A similar clinical trial of the same four drugs in children will be reported separately. ' The design of this clinical trial envisaged a total of 60 patients allocated to each drug with an average follow up period of four years. Assuming by this stage that about 25% of patients were seizure free and 80% had achieved one year of remission, the power of the trial would exceed 80% (using the log rank statistic at p = 0 05 (two tailed)) to detect improvements to 50% seizure free, or 95% achieving one year of remission, when comparing two drugs. '5 Results A total of 243 patients were randomised to the four drugs. Table 2 shows that there were no important differences between the four drug groups for age at randomisation, sex, seizure type, presence of mental handicap, neurological lesion or psychiatric history, time between first seizure and randomisation, and the total number of seizures before randomisation.
The median duration of follow up was 30 (range one to 91) months. Forty seven patients were followed up for less than one year. This included 25 patients with protocol violations, among whom 11 patients defaulted within one month of randomisation. Six patients were randomised in error, four in (14) 9 (15) 7 (11) 31 (13) Neurological lesion (No (%)) 4 (7) 11 (17) 8 (13) 8 (14) 31 (13 whom it later emerged had pseudoseizures and two alcohol induced seizures. Three patients died during the course of the study, 1-5, 3-3, and four years after randomisation.
One was a sudden unexplained death, presumed asphyxia, one was due to drowning, and one was due to a subarachnoid haemorrhage. Twenty five patients (10%) developed unacceptable side effects during the study, requiring withdrawal and substitution of an alternative drug. Over half of these (13 patients) were associated with phenobarbitone, representing 22% of patients randomised to this drug. For the other three drugs the corresponding figures were phenytoin two patients (3%), carbamazepine seven (11 %), and sodium valproate three (5%). Table 3 summarises the details. There was a significant difference between the proportion of patients withdrawn from the randomised drugs because of unacceptable side effects (X2 = 14-7, df= 3, p < 001). Patients randomised to phenobarbitone were more likely to have the drug withdrawn than those randomised to other treatments (X2 = 12-1, df = 1, p < 0-001; odds ratio 4-2; 95% confidence interval (95% CI) 1-6-10-6). Patients randomised to carbamazepine were more likely to have the drug withdrawn than those randomised to phenytoin or sodium valproate, although here the proportions of withdrawals were not statistically significant (X2 = 3-73, df = 1, p < 0-06; 3,1 (0-8, 11.8)).
The overall analysis of outcome for the 243 patients in this study showed that by three years of follow up 27 (95% CI 20-33)% were seizure free (table 4); 75 (95% CI 69-82)% had achieved a one year remission (table 5) and 42 (95% CI 33-50)% a two year remission. The four policies of treatment are compared by the percentages remaining seizure free (table 4; fig 1) or achieving a one year period of remission of all seizures (table 5; fig  2) . Differences between these percentages for the four drug groups are small with between 21% and 33% seizure free by three years of follow up, and between 72 and 77% achieving one year remission by three years. Table 6 shows, for each drug group, the estimated ratio of the odds for seizure recurrence or one year remission relative to the average odds over the four drug groups combined. The odds ratios (relative risks) for each drug indicate only small departures from the average, although with wide confidence intervals. At three years of follow up 76% remained on the randomised drug, 10% discontinued medication (after two years of remission), and 14% were taking an additional or alternative drug. Also, at three years the median dose (range) of each drug was: phenobarbitone 105 (90-180) mg, phenytoin 300 (200-450) mg, carbamazepine 600 (400-1600) mg, and sodium valproate 800 (400-2000) mg. Among patients who had failed to achieve one year of remission by three years of follow up, 20% also failed to achieve an optimum plasma concentration of the randomised drug, usually due to poor compliance. For the individual drugs the percentages were phenobarbitone 42%, phenytoin 20%, carbamazepine 7%, and sodium valproate 7-5%. The overt and perhaps subtle side effects of phenobarbitone and phenytoin may have contributed to the higher percentage with these two older drugs. 
Discussion
We have found no significant differences in efficacy between the four randomised major antiepileptic drugs in either time to first seizure recurrence or time to achieve one year of remission from all seizures. The findings are similar for the two seizure categories (tonic-clonic or partial with or without secondary generalisation). Tables 4 and 5 The largest and most influential study is that of the Veterans Administration (VA) Collaborative Group1" with which our study has some similarities and some important differences, but broadly similar conclusions. The VA group compared four drugs that included primidone, but not sodium valproate as in our study. The patients in the VA study had only partial seizures with or without secondary generalisation whereas we also included patients with tonic-clonic seizures alone. Forty two per cent of the patients in the VA group had either had antiepileptic drugs in the past (21%) or were taking such drugs at the time of referral (21%). The VA study was double blind and the objective was to rapidly achieve therapeutic blood concentrations, which, if failing to control seizures, were increased to toxic concentrations. Our study was open and designed to conform to standard clinical practice so that the small starting doses of the drugs were not increased if seizures did not recur and drugs were not increased beyond the optimum plasma concentration ranges (table 1) in the event of continuing seizures. The VA group did not utilise actuarial statistics except to analyse retention time on the four drugs, for which primidone was significantly worse, mainly due to toxicity. Comparative efficacy was assessed at sixmonthly intervals over the three year period of follow up by several measures-namely, seizure frequency per month, total number of seizures (at yearly intervals), first seizure recurrence, total seizure control after the first month of treatment (to achieve therapeutic drug concentrations), and a rating scale that incorporated seizure severity and interference with everyday life. For all these analyses, which were applied separately to partial and to secondary generalised seizures, the only significant difference to emerge was that total seizure control of partial seizures was superior with carbamazepine compared with the other three drugs at 18 months of follow up only.
During the course of our trial 25 patients (10%) were withdrawn from their randomised drug because of unacceptable side effects. Over half of these were due to phenobarbitone-namely, 13 patients representing 22% of those randomised to this drug, which was significantly more likely to be withdrawn than phenytoin (3%), carbamazepine (11%), and sodium valproate (5%). Table 3 summarises the side effects; these are well known for each drug. In the VA study" of four drugs the incidence of unacceptable toxicity leading to drug withdrawal was much higher at 20%. For the individual drugs the corresponding figures were primidone 33%, phenobarbitone 19%, phenytoin 16%, and carbamazepine 12%. Thus primidone was the major contributor to such toxicity and phenobarbitone was slightly worse than the other two drugs, although not to the degree found in our study. It seems likely that the much higher incidence of side effects overall and for the individual drugs in the VA study than in our study was related to the policy of the VA group to achieve therapeutic plasma drug concentrations soon after the onset of treatment and to increase drug dosage even higher in the event of continuing seizures. The intolerable side effects leading to withdrawal in both our own and the VA study are of an acute, subacute, or idiosyncratic kind and do not consider the issue of more subtle chronic side effects, especially of the cognitive type, which may not be severe enough to lead to drug withdrawal but which may also influence the choice of drug.'6 17 Our study has confirmed not only that there are no major differences in efficacy between the four randomised drugs for newly diagnosed tonic-clonic or partial seizures with or without secondary generalisation, but that overall the prognosis associated with each of the drugs was good. Thus by three years of follow up nearly one third of our patients have remained seizure free from the onset of treatment and three quarters of patients had entered one year of remission. A similar prognosis was noted for the four drugs in the VA study and in the two drug study by Turnbull et al,9 as had earlier been described by Elwes et aP in the first prospective but non-randomised study of phenytoin and carbamazepine monotherapy in newly diagnosed epilepsy. Similar conclusions may perhaps be inferred from the other three studies summarised in table 7, but direct comparisons cannot be made because of the short duration of follow up78 or different methods of analysis. 10 It should be stressed that none of the studies, including our own, consider the question of the efficacy of the drugs concerned, which would have required placebo controlled trials, but only the comparative efficacy of each of the drugs in relation to others also utilised as monotherapy. The efficacy of the drugs has been established in placebo controlled trials on patients with chronic epilepsy'8 but, for ethical reasons, not in newly diagnosed patients. It is widely accepted that evidence of efficacy in chronic patients, a very demanding test of any antiepileptic drug, implies efficacy in newly diagnosed patients, but as the natural history of untreated newly diagnosed epilepsy is uncertain,'9 the exact contribution of the antiepileptic drugs to the very good prognosis in such patients is also unclear. Blinding of the present study involving four drugs on a long term basis was not a practical option and would also have introduced bias due to a very large drop out rate, as in the VA study."
The findings in this and previously reported comparative efficacy studies apply only to patients with tonic-clonic seizures or partial seizures with or without secondary generalisation, the only seizure types to be studied. They do not relate to other seizure types or to specific epilepsy syndromes. Only one patient developed myoclonus after randomisation and could in retrospect be considered to have had juvenile myoclonic epilepsy. Furthermore, the patients in our own and previous studies have been randomised on the basis of clinical evidence and therefore no conclusions can be drawn about the possible implications of EEG findings for comparative antiepileptic response, which would require separate study.
It was of interest, however, that when 17 patients with focal EEG abnormalities were switched from the tonic-clonic group to the partial with or without secondary generalisation group the findings with respect to comparative efficacy for the two seizure subgroups were unchanged.
In conclusion, we have found no significant differences in the efficacy of phenobarbitone, phenytoin, carbamazepine, or sodium valproate in newly diagnosed previously untreated adult patients with two or more tonic-clonic or partial seizures with or without secondary generalisation. This is broadly in keeping with the few previously published studies of randomised comparative monotherapy trials, summarised in table 7, in particular the only other large scale randomised comparison of four drugs by the VA cooperative group." The VA study did not include sodium valproate but did include primidone. Since the preparation of this report the VA group have recently published a further multicentre comparative trial of carbamazepine against valproate and concluded that although there were no differences in efficacy between the drugs on secondarily generalised seizures, carbamazepine was superior to valproate on some measures of efficacy against complex partial seizures.20 There are important differences in trial design and analysis between the VA study and our own2' and some of the conclusions of the VA study have been questioned.2'-23 The present study confirms that the overall outcome with each of the four test drugs was good, in keeping with our own and other previous studies of the prognosis of newly diagnosed epilepsy treated with monotherapy with a standard drug. In view of the similar efficacy of the drugs in this patient population, we confirm that the choice of drug for such newly diagnosed patients may be more influenced by considerations of side effects and costs.5 6 With regard to side effects, although the overall incidence of unacceptable toxicity was much lower in our own than in the VA study, for the reasons discussed, phenobarbitone was associated with significantly more toxicity than the other three drugs.
